Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.
Diego Santos García,Carmen Labandeira Guerra,Rosa Yáñez Baña,Maria Icíar Cimas Hernando,Iria Cabo López,Jose Manuel Paz Gonález,Maria Gemma Alonso Losada,Maria José Gonzalez Palmás,Cristina Martínez Miró +8 more
TLDR
The SAFINONMOTOR study as discussed by the authors, an open-label study of the effectiveness of safinamide on non-motor symptoms in Parkinson's disease patients, was conducted in five centers from Spain and the primary efficacy outcome was the change from baseline (V1) to the end of the observational period (6 months) (V4) in the NMSS) total score.Abstract:
Some studies observed a benefit of Parkinson's disease (PD) patients after treatment with safinamide in some non-motor symptoms (NMSs). The aim of this study was to analyze the effectiveness of safinamide on NMS burden in PD. SAFINONMOTOR (an open-label study of the effectiveness of safinamide on non-motor symptoms in Parkinson's disease patients) is a prospective open-label single-arm study conducted in five centers from Spain. The primary efficacy outcome was the change from baseline (V1) to the end of the observational period (6 months) (V4) in the non-motor symptoms scale (NMSS) total score. Between May/2019 and February/2020 50 patients were included (age 68.5 ± 9.12 years; 58% females; 6.4 ± 5.1 years from diagnosis). At 6 months, 44 patients completed the follow-up (88%). The NMSS total score was reduced by 38.5% (from 97.5 ± 43.7 in V1 to 59.9 ± 35.5 in V4; p < 0.0001). By domains, improvement was observed in sleep/fatigue (-35.8%; p = 0.002), mood/apathy (-57.9%; p < 0.0001), attention/memory (-23.9%; p = 0.026), gastrointestinal symptoms (-33%; p = 0.010), urinary symptoms (-28.3%; p = 0.003), and pain/miscellaneous (-43%; p < 0.0001). Quality of life (QoL) also improved with a 29.4% reduction in the PDQ-39SI (from 30.1 ± 17.6 in V1 to 21.2 ± 13.5 in V4; p < 0.0001). A total of 21 adverse events in 16 patients (32%) were reported, 5 of which were severe (not related to safinamide). Dyskinesias and nausea were the most frequent (6%). Safinamide is well tolerated and improves NMS burden and QoL in PD patients with severe or very severe NMS burden at 6 months.read more
Citations
More filters
Journal ArticleDOI
Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson’s Disease: Past, Present, and Future
TL;DR: In this paper , the effects of monoamine oxidase-B inhibitors on motor and non-motor symptoms in PD patients, their mechanism of action, and the future development of MAO-B inhibitor therapy were discussed.
Journal ArticleDOI
The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
TL;DR: Safinamide has been used for fluctuating Parkinson's disease (PD) as add-on therapy to levodopa regimens for the management of ‘off’ episodes as mentioned in this paper.
Journal ArticleDOI
Future Therapeutic Strategies for Freezing of Gait in Parkinson's Disease
Cathy K Cui,Simon J.G. Lewis +1 more
TL;DR: A review of the literature suggests standardising how gait freezing is measured, enriching patient cohorts for preventative studies, and harnessing the power of existing data, could help lead to more effective treatments for freezing of gait and offer relief to many patients as mentioned in this paper.
Journal ArticleDOI
Present and Future of Parkinson’s Disease in Spain: PARKINSON-2030 Delphi Project
Diego Santos García,Marta Blázquez-Estrada,Matilde Calopa,Francisco Escamilla-Sevilla,E. Freire,Pedro J. Garcia Ruiz,Francisco Grandas,Jaime Kulisevsky,Lydia López-Manzanares,Juan Carlos Martínez Castrillo,P. Mir,P. Mir,Javier Pagonabarraga,Francisco Pérez-Errazquin,José María Salom,Beatriz Tijero,Francesc Valldeoriola,Rosa Yañez,Arantxa Avilés,Maria-Rosario Luquin +19 more
TL;DR: The unmet needs in diagnosis and treatment are highlighted and how crucial it is to establish recommendations for future diagnostic and therapeutic management of PD.
Journal ArticleDOI
Effectiveness of Safinamide over Mood in Parkinson's Disease Patients: Secondary Analysis of the Open-label Study SAFINONMOTOR.
Carmen M. Labandeira,Maria G. Alonso Losada,Rosa Yáñez Baña,Maria Icíar Cimas Hernando,Iria Cabo López,Jose Manuel Paz González,Maria José Gonzalez Palmás,Cristina Martínez Miró,Diego Santos García +8 more
TL;DR: The SAFINON MOTOR study as mentioned in this paper showed that SAFINamide improves mood in patients with Parkinson's disease at 6 months by reducing the BDI-II (Beck Depression Inventory-II), NMSS mood/apathy domain, and PDQ-39 (Parkinson’s Disease Questionnaire-39) emotional well-being domain.
References
More filters
Journal ArticleDOI
The Pittsburgh Sleep Quality Index: A new instrument for psychiatric practice and research.
TL;DR: The clinimetric and clinical properties of the PSQI suggest its utility both in psychiatric clinical practice and research activities.
Journal ArticleDOI
A new method for measuring daytime sleepiness: the Epworth sleepiness scale.
TL;DR: The development and use of a new scale, the Epworth sleepiness scale (ESS), is described, which is a simple, self-administered questionnaire which is shown to provide a measurement of the subject's general level of daytime sleepiness.
Journal ArticleDOI
Parkinsonism: Onset, progression, and mortality
Margaret M. Hoehn,Melvin D. Yahr +1 more
TL;DR: Controversy over the effectiveness of therapeutic measures for parkinsonism is due partially to this wide variability and to the paucity of clinical information about the natural history of the syndrome.
Journal ArticleDOI
The Parkinson's Disease Questionnaire (PDQ-39): development and validation of a Parkinson's disease summary index score
TL;DR: The profile of the PDQ-39 should be of value in studies aimed at determining the impact of treatment regimes upon particular aspects of functioning and well-being in patients with Parkinson's disease, while the PDSI will provide a summary score ofThe impact of the illness on functioning andWell-being and will be of use in the evaluation of the overall effect of different treatments.
Journal ArticleDOI
Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force
Bruno Dubois,David J. Burn,Christopher G. Goetz,Dag Aarsland,Dag Aarsland,Richard G. Brown,Gerald A. Broe,Dennis W. Dickson,Charles Duyckaerts,J. L. Cummings,Serge Gauthier,Amos D. Korczyn,Andrew J. Lees,Richard Levy,Irene Litvan,Yoshikuni Mizuno,Ian G. McKeith,C. Warren Olanow,Werner Poewe,Cristina Sampaio,Eduardo Tolosa,Murat Emre +21 more
TL;DR: The main focus of this article is to operationalize the diagnosis of PD‐D and to propose pratical guidelines based on a two level process depending upon the clinical scenario and the expertise of the evaluator involved in the assessment.
Related Papers (5)
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.
Rupam Borgohain,József Attila Szász,Paolo Stanzione,Chandrashekhar Meshram,Mohit Bhatt,D. Chirilineau,Fabrizio Stocchi,V. Lucini,R. Giuliani,Emma Forrest,P. Rice,R. Anand,M. Illiyas Sahadulla,U. Kardan,B. S. Keshava,A. Kishore,S. S. Kothari,J. M. Krishna Murthy,S. Kumar,P. Kumar Pal,N. Mehta,S. Prabhakar,S. Kr Prabhakar,S. Pradhan,A. K. Roy,C. Sankhla,P. K. Sethi,Amy Shah,N. Shankar,R. Shukla,A. Sowani,R. Srinivasa,M. Varma,D. Vasudevan,P. Vavilikolanu Sreenivas,C. U. Velmurugendran,K. Vijayan,Ovidiu Bajenaru,A. Bulboaca,A. Campeanu,D. Chirileanu,D. Muresanu,C. Panea,C. D. Popescu,Mihaela Simu,M. Ticmeanu,Tania P. Avarello,Ubaldo Bonuccelli,Roberto Eleopra,Marco Onofrj,Rocco Quatrale +50 more